Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 52 results
Filters: Author is Mellors, John W  [Clear All Filters]
Found 52 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

Boltz VF, Zheng Y, Lockman S, et al. "Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine." Proc. Natl. Acad. Sci. U.S.A.. 2011;108(22):9202-7.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Gandhi RT, Bosch RJ, Aga E, et al. "Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173." Antivir. Ther. (Lond.). 2013;18(4):607-13.
Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Wilkin TJ, McKinnon JE, A DiRienzo G, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes." J. Infect. Dis.. 2009;199(6):866-71.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
Riddler SA, Zheng L, Durand CM, et al. "Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART." Open Forum Infect Dis. 2018;5(10):ofy242.
La Rosa AM, Harrison LJ, Taiwo B, et al. "Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study." Lancet HIV. 2016;3(6):e247-58.

P

Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. "Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa." AIDS Res Treat. 2011;2011:769627.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Rutstein SE, Hosseinipour MC, Weinberger M, et al. "Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm." BMC Infect. Dis.. 2016;16(1):280.
Abbas UL, Anderson RM, Mellors JW. "Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings." J. Acquir. Immune Defic. Syndr.. 2006;41(5):632-41.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Tungsiripat M, Kitch D, Glesby MJ, et al. "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206." AIDS. 2010;24(11):1781-4.

Pages